Cornerstone Therapeutics (CRTX) +9.3% premarket after announcing that the FDA has accepted a new...

|About: Cornerstone Therapeutics Inc. (CRTX)|By:, SA News Editor

Cornerstone Therapeutics (CRTX) +9.3% premarket after announcing that the FDA has accepted a new drug application for CRTX 080, its product candidate for the treatment of hyponatremia.